NCT02575794 - Terameprocol in Treating Patients With Recurrent High Grade Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

September 30, 2023

Study Completion Date

October 4, 2023

Conditions

High Grade Glioma (III or IV)

Interventions

DRUG

Terameprocol

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (9)

Memorial Sloan-Kettering Cancer Center, New York

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

Abrams Cancer Center of the University of Pennsylvania, Philadelphia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Wake Forest University Comprehensive Cancer Center, Winston-Salem

Cleveland Clinic Taussig Cancer Center, Cleveland

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

UAB Comprehensive Cancer Center, Birmingham

Dana Farber Cancer Institute, Boston